AI news story
Alphabet's Isomorphic Labs raises $2.1 billion to scale AI drug discovery toward clinical trials
Isomorphic Labs, the AI drug research company led by DeepMind co-founder Demis Hassabis, has closed a $2.1 billion Series B round led by Thrive Capital. The funding will go toward expanding its in-house platform IsoDDE and advancing drug candidates t
Editor's take
Isomorphic Labs has secured $2.1 billion in Series B funding, significantly boosting its capacity to translate AI-driven drug discovery into clinical development.
This substantial investment underscores the growing investor confidence in AI's potential to accelerate pharmaceutical pipelines, particularly for complex diseases. Isomorphic's focus on leveraging its IsoDDE platform to move drug candidates toward human trials positions it as a key player in the increasingly competitive AI biotech landscape, potentially challenging traditional R&D timelines and impacting companies like Recursion Pharmaceuticals and Insitro.
Future watch points include Isomorphic's ability to demonstrate tangible progress in clinical stages, moving beyond preclinical proof-of-concept. The success of its platform in generating novel drug candidates that reach regulatory approval will be the ultimate measure, and its partnership strategy, if any, will also be telling.
Signal score: 4
This event was corroborated by 52 independent sources. The signal score weighs cross-source corroboration, recency, source weight and topic salience. How we rank stories.
Original reporting
This story summarises reporting published by The Decoder. Read the original article at The Decoder.